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Sutton et al. and Tweedale both criticize our 
review (Conrad and Becker 2011) because we 
did not include industry funding of a study in 
our proposed set of criteria. Fundamentally, 
we rejected “industry funding” as a credibil-
ity criterion “because questions can also arise 
about the credibility of research by scientists 
funded by government agencies or nonprofit 
organizations” (Conrad and Becker 2011). 
We accept as a given that someone has always 
paid for scientific work and that funding 
has inherent potential to influence results, 
whether it comes from industry, environmen-
tal groups, or government. It appears that at 
least one member of Sutton et al. agrees with 
us to some degree on this point, because they 
repeatedly cite Bero (1999), who endorsed 
“establishing restrictions on sponsorship, 
regardless of its source.” 
We agree that funding bias has been 
docu  mented, at least in clinical trials for phar-
maceuticals and medical procedures, although 
as Sutton et al. note, the published literature 
does not yet appear to have systematically 
studied the issue in the field of toxicology 
or epidemiology across a broad spectrum of 
substances. (Tobacco is a unique and extreme 
case and should be recognized as such, not 
cited tendentiously as indicative of all indus-
try support of research.) The guidelines for 
routine toxicity studies are publically available 
and incorporate end points reflecting both 
input from a broad spectrum of experts and 
approval by government regulatory authori-
ties [U.S. Environmental Protection Agency 
(EPA) 2011], and all such studies employ an 
entirely independent quality assurance pro-
gram documenting that facilities, equipment, 
personnel, methods, practices, records, and 
controls are in conformance with Good 
Laboratory Practice (GLP) requirements. 
The extent to which these features govern the 
design and conduct of toxicity studies miti-
gates funding bias to a large degree. 
In our review (Conrad and Becker 2011), 
we also noted that source of funding is often 
considered a “less significant” cause of pub-
lication bias than other causes [e.g., career 
advancement (publish or perish), personal 
advancement, status in one’s professional 
field, interest in obtaining positive results]. 
Sutton et al. attempt to show that the 
documents from ostensibly non  industry-
funded sources that we cited in our review 
(Conrad and Becker 2011) in fact diverge 
from the other source documents, but their 
effort is unconvincing. First, they quote the 
Bipartisan Policy Center’s statement that one 
should “consider sources of funding and any 
conflicts of interest” associated with a study 
(Bipartisan Policy Center 2009). But that 
is consistent with our review. We did not 
urge readers to dismiss questions of fund-
ing; rather, we stated that such questions 
“trigger application of the criteria” (Conrad 
and Becker 2011). The statement Sutton 
et al. quote from the Federation of American 
Societies for Experimental Biology (FASEB; 
Brockway and Furcht 2006) is taken some-
what out of context. Brockway and Furcht 
(2006) pointed out that human-subjects 
research is a case of special concern, and they 
also addressed who should be permitted to 
participate in conducting research. But their 
larger goal was as we characterized it: given 
that “academia-industry collaborations can 
benefit society,” they proposed “voluntary 
measures that guard against research bias 
and foster transparency and accountability” 
(Brockway and Furcht 2006).
It is unclear what Sutton et al.’s solu-
tion—“application of systematic and transpar-
ent methodologies to vet the science”—would 
mean in practice when one is confronted 
with a toxicological or epidemiological study. 
We suspect that their solution would end up 
looking a lot like our criteria; for example, 
Bero (1999) noted the danger of suppres-
sion by sponsors, but our criteria 2, 3, and 7 
(Conrad and Becker 2011) all militate against 
that possibility. Bero (1999) also argued that 
“sponsored investigators should retain control 
over the publication of results, regardless of 
their outcome”—our criterion 2. Tweedale 
likewise endorses “the simplicity and finality 
of forbidding outsider control of a researcher’s 
data,” but again, that is what a sponsor has to 
accept to satisfy criterion 2. 
Sutton et al. complain that our crite-
ria would not “eliminate” bias, but we do 
not claim to do that. We claim that each of 
our criteria “either a) increases confidence 
that the sponsor or experimenter did not 
shape or skew the results or interpretation 
of an experiment; or b) enables others to 
assess independently whether such shaping 
or skewing occurred.” Our criteria allow the 
scientific evidence to speak for itself. 
Tweedale criticizes our review (Conrad 
and Becker 2011) for not proposing “financial 
conflict of interests [as] the lead criteria 
to assess data quality” and for “fail[ing] to 
mention” the funding bias issue. As to 
the former, the purpose of our review was 
to address credibility, not reliability; this is 
important because generally accepted methods 
for determining data reliability have already 
been adopted and implemented by regulatory 
agencies (European Chemicals Agency 
2009; U.S. EPA 1999). As to the latter, in 
our review (Conrad and Becker 2011) we 
stated that “critics have argued that industry-
supported work has employed methods, 
animal strains, or other test features that tend 
to miss or under  estimate adverse effects,” 
so we clearly acknowledged the under  lying 
concern, even if we did not cite Tweedale’s 
references.
Beyond conflict of interest, Tweedale 
additionally mis  charac  terizes our review 
(Conrad and Becker 2011) regarding the 
topic of GLP. We did not propose exclud-
ing any relevant study simply because it did 
not follow GLP. Consistent with established 
best practices of systematic evidence-based 
reviews, we support use of transparent, objec-
tive criteria for determining data quality and 
study reliability. Such criteria allow data 
from laboratory experiments, epidemiological 
investigations, and cutting-edge mechanistic 
research from all relevant studies, GLP and 
non-GLP, and from all investigators, regard-
less of affiliation or funding source, to be 
comprehensively and systematically reviewed, 
given appropriate weight, and integrated in a 
manner that provides a robust understanding 
of the mode of action and the potential haz-
ards and risks that exposures to a substance 
could pose. These basic principles of causal 
inference are widely endorsed and practiced 
(e.g., National Research Council 2011), 
and such analysis will reveal the strengths 
and flaws of a study, independent of study 
authorship or funding.
Tweedale ignores or misunderstands 
a) previous discourse (Becker et al. 2009, 
2010; Tyl 2009) explaining how and why 
the elements of GLP often result in greater 
weight being given to such studies, and b) the 
processes by which the Organisation for 
Economic Co-operation and Development 
(OECD) develops test guidelines, in which 
experts around the world collaborate to for-
mulate, validate, update, and independently 
peer review OECD test guidelines (e.g., 
OECD 2008). When new end points or Correspondence
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metrics can be shown to be valid, relevant, 
and reliable for assessing hazard and risk, 
they can be and are incorporated into new 
and revised OECD test guidelines. In the 
meantime, nothing prohibits Tweedale or 
“independent, curious academics” from pro-
viding a full study report and all raw data 
from their studies to regulatory agencies, as 
is routinely done for GLP studies, especially 
given that supplying under  lying data will 
likely be a future requirement of journals 
(see Hanson et al. 2011). 
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American Chemistry Council, and his work 
on this letter was partially supported by the 
American Chemistry Council. R.A.B. is currently 
employed by the American Chemistry Council.
James W. Conrad Jr.
Conrad Law & Policy Counsel
Washington, DC
E-mail: jamie@conradcounsel.com
Richard A. Becker
American Chemistry Council
Washington, DC
RefeRences
Becker RA, Janus ER, White RD, Kruszewski FH, Brackett RE. 
2009. Good Laboratory Practices and safety assessments 
[Letter]. Environ Health Perspect 117:A482–A483. 
Becker RA, Janus ER, White RD, Kruszewski FH, Brackett RE. 
2010. Good Laboratory Practices: Becker et al. respond 
[Letter]. Environ Health Perspect 118:A194–A195. 
Bero  LA.  1999.  Accepting  commercial  sponsorship. 
Disclosure helps—but is not a panacea [Editorial]. BMJ 
319(7211):653–654.
Bipartisan Policy Center. 2009. Improving the Use of Science 
in Regulatory Policy. Washington, DC:Bipartisan Policy 
Center.
Brockway LM, Furcht LT. 2006. Conflicts of interest in bio­
medical research—the FASEB guidelines. FASEB J 
20(14):2435–2438.
European Chemicals Agency. 2009. Guidance in a Nutshell: 
Registration Data and Dossier Handling. Available: http://
guidance.echa.europa.eu/docs/guidance_document/
nutshell_guidance_registration_en.pdf [accessed 28 July 
2011].
Hanson B, Sugden A, Alberts B. 2011. Making data maximally 
available [Editorial]. Science 331:649.
National Research Council. 2011. A roadmap for revision. In: 
Review of the Environmental Protection Agency’s Draft 
IRIS Assessment of Formaldehyde. Washington, DC: 
National Academies Press, 151–167.
OECD  (Organisation  for  Economic  Co­operation  and 
Development). 2008. Questions & Answers Regarding 
the OECD Test Guidelines Programme (TGP). Available: 
http://www.oecd.org/dataoecd/52/33/40728679.doc 
[accessed 28 July 2011].
Tyl RW. 2009. Basic exploratory research versus guideline­
compliant studies used for hazard evaluation and risk 
assessment: bisphenol A as a case study. Environ Health 
Perspect 117:1644–1651.
U.S. EPA (U.S. Environmental Protection Agency). 1999. 
Determining the Adequacy of Existing Data. Available: 
http://www.epa.gov/hpv/pubs/general/datadfin.htm 
[accessed 28 July 2011].
U.S. EPA (U.S. Environmental Protection Agency). 2011. 
Harmonized Test Guidelines. Available: http://www.
epa.gov/ocspp/pubs/frs/home/guidelin.htm [accessed 
14 September 2011].
Errata
In the Abstract of their article “Estimating Water Supply Arsenic Levels in the New 
England Bladder Cancer Study” [Environ Health Perspect 119:1279–1285 (2011)], 
Nuckols et al. reported the following results: 
Three methods accounted for 93% of the residential estimates of arsenic concentration: direct 
measure  ment of water samples (27%; median, 0.3 μg/L; range, 0.1–11.5), statistical models of water 
utility measurement data (49%; median, 0.4 μg/L; range, 0.3–3.3), and statistical models of arsenic 
concentrations in wells using aquifers in New England (17%; median, 1.6 μg/L; range, 0.6–22.4).
The authors have revised the measurements using a more accurate method for calculating 
the median (weighted by person-years) and for reporting the range (25th–95th percentile) 
based on the values reported in Table 1 of the article, which are correct. The revised meas-
ure  ments are as follows: 
Three methods accounted for 93% of the residential estimates of arsenic concentration: direct 
measure  ment of water samples (27% EY; median weighted by person-years = 0.3 μg/L; 25–95th 
percentile range: 0.1–20.7 μg/L), statistical models of water utility measurement data (49% EY; 
weighted median 0.4 μg/L; range, 0.2–3.8 μg/L), and statistical models of arsenic concentrations in 
wells using aquifers in New England (17% EY; weighted median: 1.7 μg/L; range, 0.5–30.5 μg/L). 
The revisions do not change the study’s primary results, discussion, or conclusions. 
Nowhere else in the article is the range in concentration by water supply source summa-
rized by broad source categories.
In the article by Balazs et al. [Environ Health Perspect 119:1272–1278 (2011)], 
Equation 1 was incorrect. The corrected equation appears below.
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EHP apologizes for the error.
The November Focus article “Mountaintop Removal Mining: Digging into 
Community Health Concerns” [Environ Health Perspect 119:A476–A483 (2011)] 
erroneously stated that mountaintop removal mining is the major form of coal mining 
in West Virginia and Kentucky. Although mountaintop removal is a major form of 
coal mining in these states, underground mining still dominates, accounting for 59% 
of 2009 coal production in both West Virginia and Kentucky, according to the U.S. 
Energy Information Administration (http://www.eia.gov/cneaf/coal/page/acr/table2.
html). EHP regrets the error.